iSpecimen (ISPC)
NASDAQ:ISPC
Want to see ISPC full AI Analyst Report?
Top Page
iSpecimen
(NASDAQ:ISPC)
Select Model
Select Model
Rating:41Neutral
Price Target:
$3.00
▲(867.74% Upside)
Action:Reiterated
Date:05/18/26
The score is primarily weighed down by very weak financial performance (sharp TTM revenue decline, extremely negative margins, and ongoing cash burn) and bearish technicals (below major moving averages with negative MACD). Corporate events provide a modest offset via Nasdaq compliance and new financing, but governance-related quorum issues and the lack of earnings-based valuation support keep the overall score low.
Positive Factors
Marketplace network & platform model
iSpecimen operates a two-sided, technology-enabled marketplace that matches research buyers and biospecimen suppliers. That model can generate recurring transaction fees and network effects as suppliers and buyers concentrate on one platform, supporting durable unit economics and scalable growth if volume stabilizes.
Negative Factors
Severe revenue and margin deterioration
A sharp top-line decline and extremely negative margins indicate the core marketplace is not producing profitable scale. Deep losses erode capital and signal the business model has not delivered sustainable unit economics, making long-term recovery dependent on meaningful revenue stabilization and margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Marketplace network & platform model
iSpecimen operates a two-sided, technology-enabled marketplace that matches research buyers and biospecimen suppliers. That model can generate recurring transaction fees and network effects as suppliers and buyers concentrate on one platform, supporting durable unit economics and scalable growth if volume stabilizes.
Read all positive factors
iSpecimen (ISPC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.47M
Dividend YieldN/A
Average Volume (3M)8.88M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue Growth-87.25%
EPS Growth87.10%
CountryUS
Employees24
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,316,032
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap-0.47
Enterprise Value/Revenue-2.04
Enterprise Value/Gross Profit6.87
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
iSpecimen Business Overview & Revenue Model
Company Description
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology...
How the Company Makes Money
iSpecimen primarily makes money by facilitating transactions on its marketplace between biospecimen buyers (e.g., pharmaceutical/biotech companies, diagnostics developers, academic and clinical researchers, and other research organizations) and bi...
iSpecimen Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.03M | 1.93M | 9.29M | 9.93M | 10.40M | 11.14M |
| Gross Profit | -304.52K | 24.11K | 3.99M | 5.11M | 5.65M | 5.89M |
| EBITDA | -9.97M | -8.75M | -12.73M | -8.80M | -8.80M | -5.86M |
| Net Income | -11.10M | -10.49M | -12.50M | -11.10M | -10.25M | -8.96M |
Balance Sheet | ||||||
| Total Assets | 6.61M | 9.53M | 9.35M | 15.82M | 24.62M | 35.72M |
| Cash, Cash Equivalents and Short-Term Investments | 2.82M | 6.88M | 1.88M | 5.01M | 15.31M | 27.74M |
| Total Debt | 254.99K | 268.80K | 312.17K | 196.24K | 185.85K | 3.42M |
| Total Liabilities | 5.80M | 6.44M | 6.04M | 6.08M | 4.31M | 5.93M |
| Stockholders Equity | 814.04K | 3.09M | 3.31M | 9.74M | 20.31M | 29.79M |
Cash Flow | ||||||
| Free Cash Flow | -6.51M | -4.24M | -8.30M | -10.55M | -9.01M | -11.71M |
| Operating Cash Flow | -6.51M | -4.24M | -8.26M | -5.81M | -5.82M | -10.67M |
| Investing Cash Flow | -1.70M | -1.00M | 1.98M | -7.23M | -3.19M | -1.04M |
| Financing Cash Flow | 10.24M | 10.24M | 5.82M | 70.89K | -3.42M | 38.75M |
iSpecimen Technical Analysis
Negative
0.31
Price Trends
5.83
Negative
9.14
Negative
22.14
Negative
Market Momentum
-0.63
Positive
32.70
Neutral
7.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISPC, the sentiment is Negative. The current price of 0.31 is below the 20-day moving average (MA) of 4.84, below the 50-day MA of 5.83, and below the 200-day MA of 22.14, indicating a bearish trend. The MACD of -0.63 indicates Positive momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of 7.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISPC.
iSpecimen Risk Analysis
iSpecimen disclosed 74 risk factors in its most recent earnings report. iSpecimen reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
iSpecimen Peers Comparison
UnderperformOutperform
Sector (51)
ISPC
iSpecimen
3.40
-42.40
-92.58%
INBS
Intelligent Bio Solutions
2.83
-9.72
-77.45%
BGLC
BioNexus Gene Lab Corp
2.09
-0.89
-29.87%
BIAF
bioAffinity Technologies, Inc.
1.66
-6.83
-80.45%
iSpecimen Corporate Events
Delistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder Meetings
iSpecimen Regains Nasdaq Compliance and Raises New Capital
Positive
May 13, 2026
On May 8, 2026, iSpecimen Inc. entered into a securities purchase agreement with accredited investors for a private placement of common stock and pre-funded warrants priced around $5.12 per share, structured to avoid individual ownership above 4.9...
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
iSpecimen Completes 1-for-40 Reverse Stock Split
Neutral
May 1, 2026
iSpecimen Inc. implemented a 1‑for‑40 reverse stock split of its common stock, effective April 27, 2026, with trading on a split-adjusted basis beginning April 28, 2026, on the Nasdaq Capital Market under the symbol ISPC. The move redu...
Shareholder Meetings
iSpecimen Reschedules Annual Meeting Amid Ongoing Quorum Challenges
Negative
Apr 13, 2026
iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders on December 31, 2025, but repeatedly lacked a quorum, forcing adjournments on January 23, February 13, March 13, and April 10, 2026. The company plans to reconvene the meeting on May ...
Business Operations and StrategyProduct-Related Announcements
iSpecimen Unveils Streamlined Global Shipping for Biospecimens
Positive
Apr 10, 2026
On April 9, 2026, iSpecimen announced it has implemented a streamlined shipping model that enables direct shipment of human biospecimens from supplier sites to customers in domestic and international markets. By reducing reliance on central hub pr...
Business Operations and StrategyShareholder Meetings
iSpecimen Faces Ongoing Shareholder Quorum Challenges for Meeting
Negative
Mar 13, 2026
On December 31, 2025, iSpecimen Inc. convened its 2025 Annual Meeting of Stockholders but adjourned it due to a lack of quorum, a problem that recurred when the meeting was reconvened on January 23, 2026, February 13, 2026, and March 13, 2026. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.